摘要:
A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. In formula (I), Ar is indazole, 5-isoquinoline, 6-isoquinoline, or their N-oxide. X is -C(=Z)-, wherein Z is N-CN, NH, NR 4 , NCOR 4 , NCONR 4 R 5 , NCO-aryl, S, or O. Y and J are independently H, alkyl, aryl, aminoalkyl, -NH 2 , -CN, -OH, -O-alkyl, -O-aryl, -COOH, -COOR 4 , -CONHR 4 , -CONHCH 2 -aryl, -CONR 4 CH 2 -aryl,-NHCOR 4 , halogen, halogened alkyl, -alkyl-OR 4 , -O-alkyl-OR 4 , -alkyl-ONO 2 , O-alkyl-ONO 2 , -OCOOR 4 , -O(C=O)-aryl, -CHR 4 OH, -CH 2 OH, -CH 2 O(C=O)-aryl,-CH 2 O(C=O)-R 4 , -CHR 4 O(C=O)-aryl, -CHR 4 O(C=O)-R 4 , unsaturated carboxylic ester, substituted alkynyl, -NHSO 2 R 4 , -SR 4 , -SO 2 R 4 , -SO 2 NHR 4 , or -SO 2 NR 4 R 5 , or Y and J bond together to form a carbocylic or aromatic ring, wherein R 4 and R 5 are independently H, substituted C1-C6 alkyl, substituted aryl, cycloalkyl, alkylaryl,-alkyl-NR 6 R 7 , -alkyl-OR 6 , -alkyl-ONO 2 , -S(O) 0-2 -(alkyl-NR 6 R 7 ). R 1 , R 2 and R 3 are H, C1-C6 alkyl, cycloalkyl, aryl, alkylaryl, alkylheteroaryl, alkylheterocycle, wherein any one thereof is optionally substituted with one or more of OH, NO 2 , or NR 8 R 9 .
摘要:
A composition for improving the solubility of poorly soluble substances is provided. The composition includes about 40-99.5% by weight of cyclodextrin and/or derivatives thereof; about 0.05-10% by weight of at least one water-soluble polymer; and about 0.05-60% by weight of at least one water-soluble stabilizer.
摘要:
A composition for improving the solubility of poorly soluble substances is provided. The composition includes about 40-99.5% by weight of cyclodextrin and/or derivatives thereof; about 0.05-10% by weight of at least one water-soluble polymer; and about 0.05-60% by weight of at least one water-soluble stabilizer.
摘要:
A pharmaceutical composition with an immunomodulating function is provided, including an extract of Bupleurum obtained by grinding the Bupleurum , adding the ground Bupleurum to a solvent and isolating the extract from the solvent, wherein the Bupleurum comprises Bupleurum krlovianum, Bupleurum longiradiatum, Bupleurum smithii, Bupleurum pusillum, Bupleurum longicaule, Bupleurum salicifolium, Bupleurum scorzonerifolium and Bupleurums with at least one of the nucleotide sequences selected from a group consisting of SEQ ID NOs. 1~6 and a nucleotide sequence with no more than 1% of the nucleotide sequence divergences of SEQ ID NOs. 1-6, or combinations thereof.
摘要翻译:在免疫调节作用与一种药物组合物被提供,其中包括史密斯提取柴胡通过研磨柴胡获得的,增加接地柴胡到溶剂并从溶剂中分离提取物,worin柴胡包括柴胡krlovianum,柴胡longiradiatum,柴胡,柴胡 pusillum,柴胡longicaule,柴胡salicifolium,狭叶柴胡和Bupleurums与从一组由SEQ ID NO所选择的核苷酸序列中的至少一个。 1〜6,并用SEQ ID NOS的核苷酸序列分歧的不超过1%的核苷酸序列。 1-6,或它们的组合。
摘要:
A pharmaceutical composition for treating or alleviating autoimmune-related diseases is provided, including an extract of Amomum tsao-ko as an active ingredient and a pharmaceutically acceptable carrier, in which the extract comprises Vanillin, Tsaokoin, or the combination thereof.